ATNM

Actinium Pharmaceuticals, Inc. ATNM

NYSESmall CapHealthcare

13F Pro quality score

Rank #2,879 of 2,925

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$35.00M

Quarter to Jun 30

Net income

$27.90M

Quarter to Jun 30

Free cash flow

$-5.66M

Quarter to Jun 30

Operating margin

78.8%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$5.18M total
VANGUARD CAPITAL MANAGEMENT LLC
$1.21M-1.4%
COMPASS FINANCIAL MANAGEMENT LLC
$588.2K--
MILLENNIUM MANAGEMENT LLC
$504.3K-8.9%
ACADIAN ASSET MANAGEMENT LLC
$485.0K-17.4%
BlackRock, Inc.
$388.0K+6.7%
RENAISSANCE TECHNOLOGIES LLC
$372.9K-19.3%
GEODE CAPITAL MANAGEMENT, LLC
$318.6K-3.3%
TWO SIGMA INVESTMENTS, LP
$254.0K-23.1%
GAGNON SECURITIES LLC
$178.5K-9.5%
VANGUARD FIDUCIARY TRUST CO
$158.3K+0.8%
STATE STREET CORP
$119.8K-3.2%
Gen-Wealth Partners Inc
$103.0K-1.9%
NORTHERN TRUST CORP
$68.3K-8.1%
Qube Research & Technologies Ltd
$56.7K+220.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$55.7K-54.2%
Vontobel Holding Ltd.
$49.0K+66.7%
SNS Financial Group, LLC
$42.1KNew
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$39.2K0.0%
AM INVESTMENT STRATEGIES LLC
$29.0K0.0%
Gerald Baker Financial Group LLC
$22.2K0.0%
MAYPORT, LLC
$21.6K0.0%
NORTH STAR ASSET MANAGEMENT INC
$19.6K0.0%
WELLS FARGO & COMPANY/MN
$19.4K0.0%
OSAIC HOLDINGS, INC.
$18.5K-5.0%
XTX Topco Ltd
$13.5K-54.5%
See all 47 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ATNM

Earnings Per Share

13fpro.ai/company/ATNM

Loading ratio trend…

ATNM key financials by period

Reported revenue, net income and operating margin by fiscal year, from Actinium Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Actinium Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$90.0K$-33.9M—
FY 2023$81.0K$-48.8M—
FY 2022$1.0M$-33.0M—
FY 2021$1.1M$-24.8M—
Source: ATNM filings on SEC EDGAR →

ATNM insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Actinium Pharmaceuticals, Inc. (ATNM): stock profile, AI score and financials

Actinium Pharmaceuticals, Inc. (ATNM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATNM at 9.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,879 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Actinium Pharmaceuticals, Inc. reports quarterly revenue of $35.0M, net income of $27.9M, an operating margin of 78.8%. Top institutional holders of ATNM by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, COMPASS FINANCIAL MANAGEMENT, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. ATNM trades on the NYSE exchange and files with the SEC under CIK 1388320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Actinium Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1388320 →